CERN Investigators Publish Paper on Phase II Study
— Categories: CERN Research Articles Posted on May 14, 2015
In an open-label, two-stage, phase II study (CERN 08-01), CERN investigators aim to investigate the effect of bevacizumab and lapatinib in children with recurrent or refractory ependymoma.
Although the combination of bevacizumab and lapatinib was well tolerated in children with recurrent ependymoma, it proved ineffective.